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S U M M A R Y
Objective: No serological studies have been performed in Mexico to assess the seroprevalence of inﬂuenza
A/H1N1/2009 in groups of people according to the potential risk of transmission. The aim of this study
was to determine the seroprevalence of antibodies against inﬂuenza A/H1N1/2009 in subjects in Mexico
grouped by risk of transmission.
Methods: Two thousand two hundred and twenty-two subjects were categorized into one of ﬁve
occupation groups according to the potential risk of transmission: (1) students, (2) teachers, (3)
healthcare workers, (4) institutional home residents aged >60 years, and (5) general population.
Seroprevalence by potential transmission group and by age grouped into decades was determined by a
virus-free ELISA method based on the recombinant receptor-binding domain of the hemagglutinin of
inﬂuenza A/H1N1/2009 virus as antigen (85% sensitivity; 95% speciﬁcity). The Wilson score, Chi-square
test, and logistic regression models were used for the statistical analyses.
Results: Seroprevalence for students was 47.3%, for teachers was 33.9%, for older adults was 36.5%, and
for the general population was 33.0%, however it was only 24.6% for healthcare workers (p = 0.011). Of the
students, 56.6% of those at middle school, 56.4% of those at high school, 52.7% of those at elementary
school, and 31.1% of college students showed positive antibodies (p < 0.001). Seroprevalence was 44.6%
for college teachers, 31.6% for middle school teachers, and 29.8% for elementary school teachers, but was
only 20.3% for high school teachers (p = 0.002).
Conclusions: The student group was the group most affected by inﬂuenza A/H1N1/2009, while the
healthcare worker group showed the lowest prevalence. Students represent a key target for preventive
measures.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In April 2009, a new pandemic strain of inﬂuenza infected
thousands of persons in Mexico and the USA, and spread rapidly
throughout the world.1,2 A second wave swept through Mexico
from October to December 2009. As of July 2010, more than 214
countries worldwide had reported more than 1 million laboratory-* Corresponding author. Tel.: +52 81 88882141;
fax: +52 81 88882148/81430108.
E-mail address: lelizond@itesm.mx (L. Elizondo-Montemayor).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.07.002conﬁrmed cases of pandemic inﬂuenza A/H1N1/2009,3 while
Mexico had reported 72 548.4 However, the true number in Mexico
has not yet been determined due to a lack of serological evidence,
which might have resulted in an underestimation of the true
infection rates in the population. Reasons for under-ascertainment
include: asymptomatic cases, not all ill persons seek medical care
and have a specimen collected, not all specimens are sent for
conﬁrmation with reverse transcription PCR (RT-PCR), and cases of
negative results because of the timing of collection or the quality of
the specimen.5,6
Most of the estimations of the prevalence of the inﬂuenza A/
H1N1/2009 pandemic have been performed using indirectses. Published by Elsevier Ltd. All rights reserved.
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based on laboratory-conﬁrmed cases,7 serum cross-reactive
antibody responses to infection8 or after vaccination with seasonal
inﬂuenza vaccine,9,10 computational approaches,11 or estimations
derived in other countries from the number of cases imported from
Mexico.12,13
Some have identiﬁed seroprevalence against pandemic H1N1 in
different countries: 32% for children younger than 15 years of age
and 20% for those aged 15–24 years in England,6 5.6% in Guangxi
Province, China,9 21% in Pittsburg, PA, USA,14 from 27.7% to 42.8%
in Scotland,15 and 13% in Singapore.16 Other authors have studied
particular groups and have found a seroprevalence of 20% in
hospital staff in Singapore,17 or have measured the antibody
response to the pandemic virus resulting from previous inﬂuenza
infection or vaccination.14,18
Without a direct serological measure, predictions are subject to
substantial uncertainty. Direct measurement of the seroprevalence
provides valuable information and reliable ﬁgures about the
epidemiology of the infection, and may be useful in decision-
making about transmission models, immunization strategies, and
policy-making processes.5,11
No serological studies have been performed in Mexico to assess
the seroprevalence of inﬂuenza A/H1N1/2009 in groups of people
according to the potential risk of transmission. Therefore, this cross-
sectional study aimed to identify seroprevalence of antibodies to
pandemic inﬂuenza A/H1N1/2009 in a large population, separated
into groups by potential risk of transmission according to
occupation, at the end of the second wave of the pandemic in
Mexico. The goal was to provide a direct measure of the incidence of
infection in these groups, assessed indirectly by the seroprevalence.
2. Materials and methods
2.1. Subjects
This was a cross-sectional study of 2222 subjects whose serum
samples were collected between November 9 and December 17,
2009 in the metropolitan area of Monterrey, in northeastern
Mexico. The region has a population of 2 708 529, including
717 155 students,19 40 823 teachers,20 and 234 213 adults over 60
years of age.21 Subjects were categorized into one of ﬁve groups
and subgroups, according to the potential risk of transmission of
the inﬂuenza A/H1N1/2009 virus, depending on occupation. Table
1 shows the number, proportion, and age of the subjects in each
group. An open invitation to participate voluntarily in the study
was made to the community. Blood samples were drawn on site for
the different groups: six elementary and middle schools, four highTable 1
Seroprevalence to inﬂuenza A/H1N1/2009 virus by potential risk group of transmission
Potential risk group of transmission Sample proportion, n (%) Age, mea
Total sample 2222 (100%) 32.6 (21.
Risk groupb
Studentc 994 (45%) 14.9 (5.1
Teacherd 360 (16%) 42.0 (10.
Healthcare workere 309 (14%) 38.1 (10.
Adult >60 yearsf 189 (9%) 82.3 (9.1
General populationg 370 (17%) 40.6 (11.
SD, standard deviation; CI, conﬁdence interval.
a Seropositivity prevalence data represent percentage and 95% CI of individuals with
b Risk group: groups according to potential risk of transmission of inﬂuenza A/H1N1
stepwise) adjusting for gender, age, and group.
c Student: from elementary school to college students.
d Teacher: from elementary school to college teachers in contact with students for a
e Healthcare worker: Doctors, nurses, lab personnel, and technicians in contact with
f Adults >60 years: institutional home residents.
g General population: adults aged 20–60 years not included in the other groups andschools, one university, four institutional homes for older adults,
and three hospitals; however samples from the general population
group came from all over the metropolitan area and were collected
at a single site. Inclusion criteria were voluntary participation and
overnight fasting. Through face-to-face interviews, subjects were
asked if they had received seasonal inﬂuenza A 2008, 2009, or
pandemic inﬂuenza A/H1N1/2009 vaccinations.
2.2. Measurement of antibodies to inﬂuenza A/H1N1/2009
Overnight fasting blood samples were drawn from subjects,
centrifuged within 3 h, and frozen at 80 8C.
A virus-free ELISA method,22 based on the recombinant
receptor-binding domain of the hemagglutinin of inﬂuenza A/
H1N1/2009 virus as antigen, was employed to determine speciﬁc
antibody titers against pandemic inﬂuenza virus in serum samples.
A solution of mouse anti-histidine tag antibodies (AbD Serotec, UK)
in phosphate-buffered saline (PBS) was dispensed into microassay
plate wells (Maxisorp, Corning Inc., USA), incubated, and then
repeatedly washed. A blocking buffer (SuperBlock T20 PBS; Cat. No.
37516, Pierce Biotechnology, USA) was added to block the surface
not covered with antibodies, and the wells were then washed
again. A non-glycosylated, histidine-tagged recombinant protein
fragment of the hemagglutinin of inﬂuenza A/H1N1/2009 virus,
expressed in Escherichia coli,23 was then added. The proper folding
of this protein was demonstrated by X-ray crystallography
according to DuBois et al.24 The solution was incubated and then
washed. To test for speciﬁc bio-recognition, 100 ml of the serum
sample to be assayed (1:50 in PBS) was added to each well,
incubated, and repeatedly washed. To reveal the amount of
antibody speciﬁcally bound, 100 ml/well of an anti-human IgG
antibody solution (1:30 000 dilution in PBS–Tween 0.05%) marked
with horseradish peroxidase (Pierce Biotechnology) was used.
After incubating and washing, 100 ml/well of substrate solution (1
Step Ultra TMB-ELISA; Lot. 34028, Pierce Biotechnology) was
added. After incubation the enzymatic reaction was stopped by
adding 50 ml/well of 1 M H2SO4. The color produced by the
enzymatic reaction was evaluated by absorbance at 450 nm with a
Biotek microplate reader (Biotek, USA). Absorbance values were
normalized for each plate based on the signal of serum from one or
several subjects not exposed to inﬂuenza A/H1N1/2009. For this
study, serum samples with normalized absorbance values above
2.0 were considered seropositive for inﬂuenza A/H1N1/2009 virus.
This threshold value is considered conservative and minimizes the
possibility of false-positive samples, since typical normalized
absorbance values from non-exposed individuals ranged between
1.0  0.25 (mean  1 standard deviation).22n  SD Seropositive subjects Seropositivity prevalence, % (95% CI)a
4) 859 38.7% (36.7–40.7)
) 470 47.3% (44.2–50.4)
3) 122 33.9% (29.2–38.9)
0) 76 24.6% (20.1–29.7)
) 69 36.5% (30.0–43.6)
9) 122 33.0% (28.4–37.9)
 positive antibodies in that group.
/2009 virus; p-value = 0.011 obtained from a logistic regression model (backward,
t least 6 h/day.
 patients for more than 8 h/day.
 not pregnant.
Table 2
Seroprevalence to inﬂuenza A/H1N1/2009 virus by school level
School level potential risk group of transmission Sample proportion, n (%) Age, mean  SD Seropositive subjects Seropositivity prevalence, % (95% CI)a
Studentb 994 (100%) 14.9 (5.1) 470 47.3% (44.2–50.4)
Elementary 391 (39%) 9.8 (2.4) 206 52.7% (47.7–57.6)
Middle school 76 (8%) 13.5 (1.1) 43 56.6% (45.4–67.1)
High school 225 (23%) 16.3 (1.0) 127 56.4% (49.9–62.8)
College 302 (30%) 20.9 (2.4) 94 31.1% (26.2–36.6)
Teacherc 360 (100%) 42.0 (10.3) 122 33.9% (29.2–38.9)
Elementary 114 (32%) 39.0 (10.5) 34 29.8% (22.2–38.8)
Middle school 19 (5%) 46.9 (10.4) 6 31.6% (15.4–54.0)
High school 79 (22%) 39.8 (9.5) 16 20.3% (12.9–30.4)
College 148 (41%) 44.9 (9.5) 66 44.6% (36.8–52.6)
SD, standard deviation; CI, conﬁdence interval.
a Seropositivity prevalence data represent percentage and 95% CI of individuals with positive antibodies in that group.
b Student: p-value < 0.001.
c Teacher: p-value = 0.002.
p-Values were obtained from a Chi-square test. Logistic models (backward, stepwise) showed gender and age not to be signiﬁcant for both the student and teacher groups.
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40.8 years) claimed that they had been vaccinated against seasonal
inﬂuenza 2008 and/or 2009, and were tested for cross-reactivity
with the recombinant protein used as antigen in the ELISA assay.In
order to compare the diagnostic performance of the ELISA method
used here against standard methodologies, particularly hemag-
glutination inhibition (HI) assays, an additional set of 20 serum
samples from PCR-positive convalescent inﬂuenza A/H1N1/2009
patients and 20 non-exposed subjects (samples collected during
the year 2008, before the inﬂuenza A/H1N1/2009 pandemic onset)
were analyzed both by ELISA (samples diluted 1:50 in PBS) and HI
assays. Positive volunteers were recruited from regular patients at
Hospital San Jose´ Tecnolo´gico de Monterrey and Clı´nica Nova
during October and November 2009. Samples were taken between
2 and 24 weeks after infection. HI assays were conducted at the
Department of Infectious Diseases, St. Jude Children’s Research
Hospital, Memphis, TN, USA, according to standard methodolo-
gies.22
2.3. Statistical analysis
Sample size was calculated using a 95% conﬁdence level and a
desired conﬁdence interval of 3%. The estimated study proportion
was 30%, according to the seroprevalence in probable cases of
inﬂuenza A/H1N1/2009 reported in Mexico by mid 2009.25
The prevalence of inﬂuenza A/H1N1/2009 seropositivity is
presented as the percentage of individuals with positive antibodies
tested in each group with its 95% conﬁdence interval in
parenthesis. We used the Wilson score method to obtain the
conﬁdence intervals. Differences in proportions were evaluated by
Chi-square tests. Multivariate analysis was performed by logistic
regression models (backward, stepwise) with the presence or
absence of antibodies as a dependent dichotomous variable and
adjusting for risk of transmission groups, age groups (age grouped
into decades), and gender where appropriate. The resulting models
were found adequate by the Hosmer–Lemeshow goodness of ﬁt
test. Multicollinearity between occupation risk and age was
evaluated through calculation of the corresponding variance
inﬂation factor (VIF) value. The gender variable was found not
signiﬁcant in all models. A two-tailed p-value of < 0.05 was
considered statistically signiﬁcant. All analyses were performed
with SPSS Statistics 17.0 software (IBM-SPSS, USA).
3. Results
There was a signiﬁcant difference in the percentage of serum
samples that tested positive for antibodies to pandemic inﬂuenza
A/H1N1/2009 virus among the diverse risk groups. Students hadthe highest seroprevalence (47.3%), followed by older adults
(36.5%), while healthcare workers had the lowest (24.6%). The
result for the VIF for multicollinearity between occupation risk and
age was 2.4, which represents a low multicollinearity (Table 1). The
percentage of persons who tested positive for inﬂuenza A/H1N1/
2009 was signiﬁcantly higher for the middle and high school
student groups (56.6% and 56.4%, respectively), followed closely by
the elementary school children group. Seroprevalence for the
elementary and middle school teacher groups (29.8% and 31.6%,
respectively) was signiﬁcantly lower than that of their correspond-
ing student groups (Chi-square p-value < 0.001). The lowest
percentage was observed for high school teachers (20.3%), while a
striking increase in seroprevalence was noted for college teachers
(44.6%), which was even higher than for college students (31.1%)
(Table 2).
None of the participants had been vaccinated against inﬂuenza
A/H1N1/2009, while 28.0% had received seasonal vaccination for
inﬂuenza A 2008 and 33.5% for seasonal inﬂuenza A 2009.
Regarding age cohorts, grouped in decades, the percentage of
persons who tested positive for antibodies against inﬂuenza A/
H1N1/2009 was highest in the 6–10 years group (51.1%), followed
closely by the 11–20 years group (49.0%). A decreasing seropositive
trend was seen as age increased up to those aged 60 years (25.2%),
but then an increase in seroprevalence was seen for those >60
years of age, reaching 41.0% in those aged 71–80 years (Table 3).
The Chi-square test showed there was a signiﬁcant difference in
the proportions of seroprevalence for the different age cohorts
(p < 0.000).
The percentage of positive samples from the 950 subjects
vaccinated against seasonal inﬂuenza 2008 and/or 2009, according
to ELISA, was 35.1%, which was not signiﬁcantly different to the
percentage of the non-vaccinated subset, at 41.4% (p = 0.139,
adjusted for sex and age). None of the 950 subjects tested showed
cross-reactivity with the recombinant protein used as antigen in
the ELISA assay.The sensitivity and speciﬁcity of the ELISA method,
considering a threshold value of normalized absorbance of 2.0,
were 85% and 95%, respectively. In the comparative analysis of the
ELISA method and HI assays, the ELISA method determined 85% of
the positive cases as such, while only 50% of the positive cases were
precisely diagnosed by HI (when the conventional threshold of
1:40 dilution for agglutination inhibition was considered an
indicator of seropositivity). More details on the comparative
performance of the ELISA method used here and the conventional
HI assay is presented elsewhere.22,26
The ELISA method used here yields adequate reproducibility
and a high signal/noise ratio within determinations in the same
microplate and among different microplates.27 Using a normalized
absorbance value of 2.0, the method was able to discriminate
Table 3
Seroprevalence to inﬂuenza A/H1N1/2009 virus by gender and age grouped into decades
Characteristic Sample proportion, n (%) Age, mean  SD Seropositive subjects Seropositivity prevalence,
% (95% CI)a
Genderb
Male 870 (39%) 28.4 (19.8) 364 41.8% (38.6–45.1)
Female 1352 (61%) 35.2 (22.0) 495 36.6% (34.1–39.2)
Age grouped into decadesc
6–10 229 (11%) 8.2 (1.5) 117 51.1% (44.7–57.5)
11–20 623 (29%) 15.8 (2.8) 305 49.0% (45.0–52.9)
21–30 321 (15%) 24.6 (3.0) 119 37.1% (32.0–42.5)
31–40 311 (14%) 35.7 (2.9) 84 27.0% (22.4–32.2)
41–50 313 (14%) 45.3 (2.9) 91 29.1% (24.3–34.3)
51–60 143 (7%) 54.8 (2.9) 36 25.2% (18.8–32.9)
61–70 45 (2%) 64.5 (2.7) 16 35.6% (23.2–50.2)
71–80 61 (3%) 76.2 (2.8) 25 41.0% (29.5–53.5)
81–90 80 (4%) 85.5 (2.5) 30 37.5% (27.7–48.5)
91+ 34 (2%) 94.5 (3.4) 13 38.2% (23.9–55.0)
SD, standard deviation; CI, conﬁdence interval.
a Seropositivity prevalence data represent percentage and 95% CI of individuals with positive antibodies in that group.
b Gender: p-value = 0.259.
c Age cohort: p-value < 0.000; 62 missing values for decade of birth.
p-Values were obtained from a logistic model adjusted for gender and age.
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week of infection, and at least up to the 24th week of exposure.
Assay sensibility was further validated against results from HI
assays. A previous report showed that all members in a pool of 14
samples diagnosed as positive by HI exhibited normalized
absorbance values higher than 1.5, and 85% of them exhibited
normalized absorbance values higher than 2.0.22 In general, high HI
titers (>1:320) were correlated with normalized absorbance
values higher than 4.0. In addition, the ELISA method and the HI
assay were used to diagnose a pool of 17 serum samples
corresponding to convalescent H1N1/2009 patients diagnosed
by RT-PCR. All samples determined as positive by HI (10 samples)
were also positive by ELISA. While sensitivity of the HI assay was
10/17 = 58.88% (using a positivity criterion of inhibition at
dilutions higher or equal to 1:40), the ELISA method recognized
100% of samples as positive when a threshold of 1.5 was used, and
85% of samples as positive when a threshold of 2.0 was used.27
With this very same threshold, 3.88% of false-positives were
observed when 100 serum samples from non-exposed individuals
(samples collected in 2008, before the onset of the pandemic) were
used.
4. Discussion
The inﬂuenza A/H1N1/2009 virus has resulted in the ﬁrst
inﬂuenza pandemic in more than four decades.28 A need for more
comprehensive serosurveys to understand infection rates and
population immunity has emerged, since relying on laboratory-
conﬁrmed cases limits the ability to understand the full impact and
severity of the epidemic.29 This study, which examined real-time
seroprevalence at the end of the fall wave in Mexico,30,31
contributes to our understanding of the spread of the pandemic
throughout the population. It may also explain some of the
differential distributions not only of affected age groups, but
particularly of certain risk groups, according to potential risk of
infection with the virus. To our knowledge, this is the ﬁrst study of
this type.
The results of this study of 2222 people indicate an indirect sign
of infection of speciﬁc risk groups according to the seroprevalence
found. We found no difference in the seroprevalence between
genders. The proportion of people with positive antibodies to
inﬂuenza A/H1N1/2009 virus was signiﬁcantly higher for students
as a group (47.3%), followed by teachers (33.9%), and closely by the
general population (33.0%), while that of healthcare workers wasthe lowest (24.6%). Interestingly, teaching students (high school)
with a high seroprevalence (up to 57%) seems to be associated with
a low seroprevalence (down to 30%). Even though their respective
mean ages were similar, 42.0  10.3 years for teachers and
40.6  11.9 years for the general population, college teachers showed
a signiﬁcantly higher seroprevalence (44.6%) compared to the general
population (33.0%) (Chi-square p = 0.013), which might be due to
their close exposure to students (Table 1). We also have to consider
that the different prevalence rates in the teachers in contact with
diverse student groups may reﬂect baseline differences in the
prevalence of cross-reactive antibodies. Intense preventive measures
and increased awareness might account for the lowest prevalence in
the healthcare workers group. Older adults living in institutional
homes showed a prevalence of 36.5%, which might be explained by
previous exposure to a 1918-like H1N1 virus, as has been
documented.5,6,18,28,32 The general population group included people
from diverse occupations with varied contact and socialization
patterns, which might have placed them at lower risk. However, we
have to consider that data from such a heterogeneous group are
difﬁcult to interpret.
Students are more predisposed to transmission and spread of
the virus because of their greater close contact within limited
classroom spaces for 6–8 h/day. This is particularly the case for
elementary and middle school students, which might explain their
strikingly higher seroprevalences (52.7% and 56.6%, respectively).
High school students showed a higher prevalence (56.4%)
compared to college students (31.1%). This might be explained
by the nature of socialization outside of school and by greater
contact during sports and cultural activities within the school.
These ﬁndings are consistent with the high level of susceptibility in
children and adolescents, and the increased potential for acquisi-
tion and subsequent transmission of inﬂuenza that occurs within
schools.33 The milder disease seen with this pandemic may also
have contributed to its increased spread.5,18
Concerning seroprevalence according to age grouped into
decades (Table 3), there was a signiﬁcantly higher prevalence of
antibodies to inﬂuenza A/H1N1/2009 in those aged 6–10 years
(51.1%) and 11–20 years (49%), with a decreasing tendency
apparent as age advanced up to those aged 51–60 years (25.2%),
but then rising again in those >60 years (35.6–41.0%). Half of those
in the population aged 20 years or younger were seropositive and
the proportion was almost double that of people aged 31–60 years.
From April 2009 to December 2009, there were 67 982 conﬁrmed
cases/800 deaths in Mexico, distributed by age group as follows: 0–
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21–30 years: 12 950/156; 31–40 years: 7261/182; 41–50 years:
5063/146; 51–60 years: 3082/135; 61–70 years: 1280/43; non-
speciﬁed: 632/0. In our study participants, the prevalence was
highest in those aged 5–10 years (51.1%), followed by the 10–19
years group (49.0%), then by the 20–29 years group (37.1%),
declining thereafter. Approximately 70% of the deaths occurred in
those aged 20–55 years. Compared to the incidence rates of
conﬁrmed cases that occurred among those aged 5–10, 11–20, and
21–30 years, our study participants aged 5–10 years had the
highest seropositivity rate. This might indicate that this particular
very young group suffered from asymptomatic transmission
more than the other groups. Immunization strategies in this group
of the young and susceptible should be reinforced to reduce
transmission.
Our data showed a higher prevalence for all age and cohort
groups than has been reported from other countries, such as the
USA,5,14 Singapore,16 and England,6 but were similar to ﬁndings
from Scotland.15 Similarly, prevalence in older adults has differed
greatly.9,18,32,34,35 This higher prevalence in Mexico might partly be
explained by the timing of the epidemic. The ﬁrst reported cases of
conﬁrmed inﬂuenza A/H1N1/2009 occurred in Mexico in April
2009. At the time, a lack of awareness might have resulted in
infection of a greater proportion of the population during the ﬁrst
wave, since no preventive measures were applied until about 1
month later. In contrast, in other countries, preventive measures
were applied prior to the onset of the epidemic. We also have to
consider that studies from these countries used the conventional
HI method for measuring strain-speciﬁc inﬂuenza antibodies, and
our results derive from the ELISA-based method described.
To estimate the incidence of 2009 pandemic H1N1, several
approaches have been used that combine data from established
surveillance systems and from mathematical and computational
models.7,11,36–38 Estimates such as these probably underestimate
the total number of people infected. One study determined the
reference range for the number of cases in Mexico: 121 000 to
1 394 000.11 Two other studies reported a ratio of infected cases in
Mexico as low as 1 in 100, derived from infected travelers, which
are orders of magnitude larger than those conﬁrmed by the
Mexican authorities.12,13
The region we assessed has a population of 2 708 529, including
717 155 students,19 40 823 teachers,20 and 234 213 adults over 60
years.21 There are no data in Mexico for the seroprevalence in the
community after the ﬁrst wave, nor are there data for the possible
rate of waning of antibodies acquired at that time, in order to
estimate if immunity gained in the ﬁrst wave could have persisted at
the time of the present study. A between-wave collection would have
been desirable. Although we do not have information on baseline
seropositivity to calculate the actual attack rate, our results might be
an indication that the number of conﬁrmed cases in Mexico could be
a gross underestimation of the actual number of infections.39 Other
countries have demonstrated an underestimation of cases as
well.12,13,40 This highlights the usefulness of serosurveys for a more
complete understanding of the extent of the infection with the
pandemic virus,41 and for proper evaluation of several disease
features of high relevance for public health policies.11
Our results suggest that serum antibodies from individuals
exposed to other recently circulating inﬂuenza strains (included in
the 2008 and 2009 seasonal inﬂuenza vaccines) do not exhibit
signiﬁcant cross-reactivity, as tested by the ELISA method used
here.
The present study has a number of limitations. We did not
include children under 6 years old because of technical difﬁculties
with schools that manage this young age group. There are no data
on baseline seropositivity, which might be important for incidence
calculations.8 Population recruitment was performed by openinvitation; therefore, it is difﬁcult to exclude a population bias, as
those most interested or with more self-awareness of inﬂuenza A/
H1N1/2009, or people who had inﬂuenza-like symptoms may have
had a greater tendency to participate. Finally, the study was also
carried out at the end of the second wave of inﬂuenza, so the
seroprevalence in all risk groups could change, since the sampling
interval may not have been long enough for antibody generation in
some of the study participants.
The major contribution of this study is that it makes a direct
estimation of the post-wave seropositivity to inﬂuenza A/H1N1/
2009 virus in the metropolitan area according to the potential of
transmission risk and distribution of the groups. Students might be
considered as a group for vaccination to a higher extent.
In conclusion, this serological study shows the true extent of
inﬂuenza A/H1N1/2009 infection in Monterrey, Mexico in 2009 for
the selected risk groups, and has provided valuable insights into
the epidemiology of the disease by potential transmission risk
groups, especially that of students. Although we have to consider
the fact that there was no baseline prevalence with which to
compare the post-pandemic prevalence across the different age
groups, and the limited data on the sensitivity and speciﬁcity of the
ELISA method by age, these ﬁndings could be applicable to other
countries that have experienced a similar pattern of infection.
Continued studies to assess changes in the population over time
will further improve our understanding of the transmission of
inﬂuenza A/H1N1/2009, particularly the role of children and
adolescents in transmission, and will also provide more robust
data regarding disease burden, intervention strategies, and future
prevention policies.
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